This is an exciting time for the cell and gene therapy (CGT) industry. From rapid growth in pending and newly commercialized therapies to increased investments in new and existing facilities, to acquisitions and business partnerships, opportunities for transformation abound in personalized medicine for cancer or rare disease patients. With growth, however, comes a challenge to develop new ways of working to meet the unique and complex requirements for biotech and pharmaceutical companies and their extended ecosystems to offer long-lasting and effective treatments.